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Background. Expected survival is a major factor influencing extent of treatment for symptomatic spinal bone metastases (SBM). Pre-
dictive models have been developed, but their use can lead to over- or undertreatment.. The study objective was to identify prognostic
factors associated with survival in patients with symptomatic SBM and to create a validated risk stratification model.
Methods. All patients whowere treated for symptomatic SBM between 2001 and 2010 were included in this single center retrospective
study. Medical records were reviewed for type of primary cancer, performance status, presence of visceral, brain and bonemetastases,
number and location of spinal metastases, and neurological functioning. Performance status was assessed with the Karnofsky per-
formance score and neurological functioning with the Frankel scale. Analysis was performed using Kaplan-Meier curves, univariate log-
rank tests, Cox regression models, and Harrell’s C statistic.
Results. A total of 1 043 patients were studied. Themost prevalent tumors were those of breast (n¼ 299), lung (n¼ 250), and prostate
(n¼ 215). Median follow-up duration was 6.6 years, and 6 patients were lost to follow-up. Based on the results of the uni- and multi-
variate analyses, 4 categories were created. Median survival in category Awas 31.2 months (95% CI, 25.2–37.3 months), 15.4 months
(95% CI, 11.9–18.2 months) for category B, 4.8 months (95% CI, 4.1–5.4 months) for category C, and 1.6 months (95% CI, 1.4–1.9
months) for category D. Harrell’s C statistic was calculated after the model was applied to an external dataset, yielding a result of 0.69.
Conclusion. Assessing patients according to the presented model results in 4 categories with significantly different survival times.
Keywords: spinal metastases, survival, stratification.
Metastases to the spinal column are a frequently observed com-
plication of end-stage malignant disease. Depending on their ex-
tent and localization, they cause a variety of clinical symptoms
ranging from pain to neurological deficits and even paraplegia.
These spinal bone metastases (SBM) most commonly arise
from the posterior part of the vertebral body. When they extend
into the epidural space and compress the spinal cord, the clinical
entity is called malignant epidural spinal cord compression.1
Due to improvements in systemic treatment options for the
primary tumor, overall survival times for patients suffering from
metastatic disease are on the rise. Most likely, this will result in
a prolonged palliative phase in which the incidence of patients
presenting with symptomatic SBM will increase. It has been well
established that treatment with radiotherapy and/or surgery can
be beneficial to patients presenting with pain, neurological deficit,
or both.2–6 However, the most optimal treatment algorithm for
individual patients has not yet been optimized. In practice, the
treating physician will match extent and type of treatment not
only to a patient’s clinical presentation but also to the expected
survival time, thus balancing the increase in morbidity and mor-
tality associated with more extensive treatment against the
expected gain in quality of life.
Models to aid in therapy selection based on expected survival
time have been developed by Tomita,7 Tokuhashi,8,9 Bauer,10,11
and our own group.4 These models encompass prognostic factors
such as primary tumor type, amount and location of spinal metas-
tases, presence of visceral, brain and extraspinal bone metastases,
functional status, and neurological status. However, clinical applic-
ability seems limited due to over- or undertreatment, and the exist-
ingmodels fall short, especially when predicting a brief survival.12,13
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The goal of this study was to identify risk factors associated
with survival and to develop a validated survival risk stratification
model for patients with symptomatic SBM.
Materials and Methods
In this single center retrospective cohort study, all patients trea-
ted for metastases in the spinal column between January 2001
and December 2010 at a tertiary referral hospital in the Nether-
lands were included. Patients were identified through database
searches linking treatment and diagnostic codes and database
searches based on surgical coding. Information on date of
death was obtained from medical records or by contacting the
general practitioner.
Local treatment consisted of external beam radiotherapy for
pain or minor neurological deficit, surgery for rapidly progressive
or severe neurological deficit and instability, or a combination of
both treatment modalities. Concomitant systemic anticancer
treatments, such as chemotherapy and bisphosphonates, were
considered to be secondary to the local treatment. For external
validation of the final model, the database of the Dutch Bone Me-
tastasis Study (DBMS) was used.14
Due to the retrospective nature of the study, it was exempt
from medical ethics review according to the Dutch Central Com-
mittee on Research Involving Human Subjects.
The primary data sources were the patient’s’ clinical files, radi-
ology reports, and admission forms. Baseline variables obtained
before start of treatment were sex, age, primary tumor, location
and number of SBM, the presence of visceral and/or brain metas-
tases, the presence of extraspinal bone metastases, pretreat-
ment functioning according to the KPS,15,16 and neurological
functioning according to the Frankel classification.17
The primary tumors were categorized based on the Tomita
classification.7 The original classification used growth speed
alone to assign a primary tumor into 1 of 3 groups. However, as
growth speed is not the only factor determining survival, we
renamed the classification “clinical profile” to encompass other
contributing factors such as availability of effective systemic
treatment options for the primary tumor. The clinical profile of
a primary tumor was considered to be favorable, moderate, or
unfavorable.
Performance status was dichotomized into normal functioning
(KPS 100%–80%) and impaired functioning (KPS 70%–10%).
Neurological functioning was inferred from clinical exams and
divided into 3 groups: no deficit present (Frankel E), minor
motor or sensory deficit (Frankel D), and major motor or sensory
deficit (Frankel A, B, C). The number of spinal and extraspinal bone
metastases was obtained from radiology reports and further sub-
divided in 3 categories according to Tokuhashi.9
Statistical Analysis
Survival time was calculated as the difference between start of
treatment for the spinal metastasis and date of death or the
last follow-up recorded. Survival curves were estimated using
the Kaplan-Meier method. Follow-up was assessed by employing
the reverse Kaplan-Meier method.18 Cox proportional hazard
models were fitted using Collett’s method (a univariate analysis
followed by multivariate backward and multivariate forward se-
lection).19 Harrell’s C statistic was used for external validation of
the predictive accuracy of the presented model.20 It estimates
the probability of concordance between predicted and observed
responses. Survival curves were compared using log-rank tests.
A P value of ,.05 was considered statistically significant. All ana-
lyses were performed using SPSS 20.0 (SPSS Inc.)
Results
A total of 1 301 patients were treated for symptomatic spinal me-
tastases during the study period. After excluding patients with dir-
ect ingrowth of a primary tumor into the vertebra (n¼ 23), patients
with bone metastases in the sacral or sacroiliac region (n¼ 105),
leptomeningeal metastases (n¼ 24), intradural metastases (n¼
14), metastases deriving from primary tumors of hematological
or of unknown origin (n¼ 44), and metastases deriving from rare
primary tumors (n¼ 42), 1 049 patients remained eligible for ana-
lysis. Primary tumors classified as adenocarcinoma of unknown
primary were not excluded. Six patients moved abroad shortly
after finishing treatment and were lost to follow-up (Fig. 1).
Table 1 summarizes the characteristics of the 1 043 patients
studied, of whom 542 (52%) were male and 501 (48%) were fe-
male. The mean age at start of treatment was 64.8 years (SD+
12.5 years). At presentation, the majority of patients had no (n¼
518; 50%) or only minor (n¼ 403; 39%) neurological complaints.
Median follow-up was 6.6 years. The overall median survival
was 4.8 months (95% CI, 4.3–5.4 months). In total 984 patients
(94%) died during follow-up with amedian survival of 4.3 months
(95% CI, 3.8–4.9 months). Two-hundred-and-forty-three (23%)
patients died within 6 weeks after starting treatment, whereas
179 (17%) patients survived for more than 2 years.
The most prevalent primary tumors were breast cancer (n¼
299), lung cancer (n¼ 255), prostate cancer (n¼ 215), kidney
cancer (n¼ 60), and colon cancer (n¼ 55) (Table 2). Thirty per-
cent of all patients were classified as having a favorable clinical
profile with a median survival of 18.6 months (95% CI, 15.1–
22.1 months), followed by 29% with a moderate profile and a
median survival of 5.9 months (95% CI, 4.8–7.0 months), and
41% with an unfavorable profile and a median survival of 2.2
months (95% CI, 1.9–2.6 months) (Fig. 2).
Radiotherapy was the most commonly used primary treat-
ment in a total of 997 patients (95%). Only 46 patients (5%)
underwent surgery. See Table 3 for the radiotherapy regimens
and surgical techniques used.
The DBMS database consisted of 342 SBM cases treated with
radiotherapy. Median follow-up was 2.2 years, and overall median
survival was 8.9 months (95% CI, 7.4–10.3 months). In total, 258
Fig. 1. Patient flow diagram.
Bollen et al.: Prognostic factors survival spinal metastases
992
patients (76%) died during follow-up. Further details of the pa-
tient population are published elsewhere.4
Analysis of the Entire Cohort
Results of the univariate and multivariate analyses are detailed in
Table 4. The 3 clinical profiles (moderate HR 1.6; 95% CI, 1.3–2.1;
P,.001) (unfavorable HR 3.5; 95% CI, 2.9–4.4; P, .001), the
KPS (HR 1.9; 95% CI, 1.6–2.2; P, .001), and the presence of
visceral metastases (HR 1.5; 95% CI, 1.3–1.7; P, .001) were
shown to be of influence on survival. The Frankel classification,
the number and location of the spinal metastases, and the pres-
ence of brain and extraspinal bone metastases did not influence
survival.
Analysis Stratified for Clinical Profile
Results of the univariate and multivariate analyses for the 3 clin-
ical profiles are illustrated in Table 5. A poor KPS (HR 1.7; 95% CI,
1.3–2.2; P, .001), the presence of visceral metastases (HR 2.0;
95% CI, 1.5–2.7; P, .001), and the presence of brain metastases
Table 2. Primary tumor, related survival, and clinical profile
Primary tumor Number (%) Median Survival
months (95% CI)
Profile
Breast 299 (29) 18.6 (14.9–22.2) Favorable
Thyroid 13 (1) 4.8 (0.0–24.9) Favorable
Prostate 215 (21) 6.6 (5.2–8.1) Moderate
Kidney 60 (6) 4.5 (2.6–6.4) Moderate
Ovary 8 (1) 4.9 (2.3–7.6) Moderate
Osteosarcoma 9 (1) 6.3 (0.0–12.6) Moderate
Uterine sarcoma 4 (, 1) 4.6 (0.0–10.0) Moderate
Lung 250 (24) 1.9 (1.5–2.4) Unfavorable
Colon 55 (5) 3.2 (1.8–4.5) Unfavorable
UCC 27 (3) 1.7 (0.9–2.6) Unfavorable
ACUP 22 (2) 2.4 (0.9–3.8) Unfavorable
Esophagus 20 (2) 1.7 (0.1–3.3) Unfavorable
Melanoma 17 (2) 1.2 (0.5–1.8) Unfavorable
Pancreaticobiliary 11 (1) 1.7 (1.2–2.2) Unfavorable
Ewing’s sarcoma 10 (1) 1.9 (0.3–3.5) Unfavorable
Cervix 7 (1) 2.3 (0.0–5.7) Unfavorable
Endometrium 5 (1) 1.9 (0.9–3.0) Unfavorable
Stomach 4 (,1) 1.2 (0.2–2.3) Unfavorable
Liver 4 (,1) 7.5 (0.0–15.8) Unfavorable
Tongue 3 (,1) 0.8 (0.7–0.8) Unfavorable
Abbreviations: ACUP, adenocarcinoma of unknown primary; CI,
confidence interval; UCC, urothelial cell carcinoma.
Table 1. Population characteristics
Characteristic n (%)
Sex
Male 542 (52)
Female 501 (48)
Age (mean, years+SD) 64.8+12.5
Clinical profile
Favorable 312 (30)
Moderate 296 (28)
Unfavorable 435 (42)
Location treated spinal metastases
Cervical only 40 (4)
Cervicothoracic 121 (12)
Thoracic only 256 (24)
Thoracolumbar 275 (27)
Lumbar only 309 (30)
Diffuse 42 (3)
Number spinal metastases
1 326 (31)
2 191 (19)
3 or more 526 (50)
Number extraspinal bone metastases
None 370 (35)
1 or 2 287 (28)
3 or more 386 (37)
Visceral metastases
Present 380 (36)
Not present 663 (64)
Brain metastases
Present 71 (7)
Not present 972 (93)
Karnofsky performance status
Normal (100%–80%) 387 (37)
Impaired (70%–10%) 607 (58)
Missing 49 (5)
Frankel classification
No deficit (E) 518 (50)
Minor motor or sensory deficit (D) 403 (39)
Major motor or sensory deficit (A, B, C) 112 (10)
Missing 10 (1)
Abbreviation: SD, standard deviation.
Fig. 2. Survival curves of clinical profiles.
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(HR 1.8; 95% CI, 1.1–3.0; P¼ .016) were shown to have an asso-
ciation with survival in the favorable profile. In the moderate and
unfavorable profiles, only the KPS affected survival (HR 2.3; 95%
CI, 1.7–3.0; P, .001 and HR 1.9; 95% CI, 1.5–2.3; P, .001,
respectively).
Training Data Set and Validation Data Set
Based on the results of the 3 multivariate analyses, the cohort
was divided into 8 groups (Fig 3A). By comparing the median sur-
vival of the groups, 4 final categories (A, B, C, and D) were created
(Table 6). Patients in category A had a median overall survival of
31.2 months (95% CI, 25.2–37.3 months), compared with 15.4
months (95% CI, 11.9–18.2 months) for patients in category B,
4.8 months (95% CI, 4.1–5.4 months) for patients in category
C, and 1.6 months (95% CI, 1.4–1.9 months) for patients in cat-
egory D (Fig. 3B and Table 7). Harrell’s C statistic was 0.71 when
calculated based on the training data set.
Table 3. Treatment details
Treatment n (%)
Overall
Radiotherapy only 997 (95)
Surgery and radiotherapy 39 (4)
Surgery only 7 (1)
Radiotherapy regimens
1×8 Gy 445 (43)
2×8 Gy 169 (16)
6×4 Gy or 5×4 Gy 322 (31)
Other – Total dose .24 Gy 100 (10)
Surgery
Minimal invasive 10 (22)
Limited decompression and fixation 23 (50)
Extended decompression and fixation 13 (28)
Table 4. Results of the uni- and multivariate analyses
Univariate Log-Rank Test P value
Clinical profile (Favorable/Moderate/Unfavorable) ,.001
Karnofsky (100%-80%/70%-10%) ,.001
Frankel classification (ABC/D/E) ,.001
Visceral metastases (Yes/No) ,.001
Brain metastases (Yes/No) .012
Number spinal metastases (1/2/≥3) .983
Bone metastases (0/1/≥2) .093
Location spinal metastases (C/CT/T/TL/L/D) .836
Multivariate Cox Regression Model HR 95% CI P value
Clinical profile
Favorable – – ,.001
Moderate 1.6 1.3–2.1 ,.001
Unfavorable 3.5 2.9–4.4 ,.001
Karnofsky performance status
Normal (100%-80%) – – ,.001
Impaired (70%-10%) 1.9 1.6–2.2 ,.001
Visceral metastases
Not present – – ,.001
Present 1.5 1.3–1.7 ,.001
Abbreviations: C, cervical; CI, confidence interval; CT, cervicothoracic; D, diffuse; HR , hazard ratio; L, lumbar; T, thoracic; TL, thoracolumbar.
Table 5. Results of the uni- and multivariate analyses stratified for clinical
profile
Univariate Analysis Favorable Moderate Unfavorable
(n¼ 312) (n¼ 296) (n¼ 435)
Performance status ,0.001 ,0.001 ,0.001
Visceral metastases ,0.001 0.086 0.165
Brain metastases 0.009 0.482 0.528
Frankel classification 0.043 0.757 0.248
Number spinal metastases 0.054 0.469 0.243
Bone metastases 0.078 0.120 0.943
Location spinal metastases 0.657 0.196 0.867
Cox regression models HR 95% CI P value
Model 1: Favorable profile
Performance status ≤70% 1.7 1.3–2.2 ,.001
Visceral metastases present 2.0 1.5–2.7 ,.001
Brain metastases present 1.8 1.1–3.0 0.016
Model 2: Moderate profile
Performance status ≤70% 2.3 1.7–2.9 ,.001
Model 3: Unfavorable profile
Performance status ≤70% 1.9 1.5–2.3 ,.001
Abbreviations: CI, confidence internal; HR, hazard ratio.
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Patients in category A of the validation data set had a median
survival of 16.3 months (95% CI, 11.1–21.6 months), compared
with 12.8 months (95% CI, 9.5–16.0 month) for category B, 7.0
months (95% CI, 5.1–9.0 months) for category C, and 3.6 months
(95% CI, 2.6–4.6 months) for category D (Fig. 3C and Table 7). The
C statistic based on the validation data set was 0.69.
Discussion
In this retrospective study of 1 043 patients treated for symptom-
atic SBM, it has been shown that the clinical profile of the primary
tumor, performance status and—in the subgroup of a favorable
clinical profile only—the presence of visceral and brain metasta-
ses is associated with survival. Other prognostic factors, such as
the presence of extraspinal bone metastases, number and loca-
tion of spinal metastases, and neurological functioning, did not
show a significant effect on survival.
The most important limitation of this study is its retrospective
design. Due to the fact that all patients were treated in a single
institution, clinical information was readily available, including
radiology reports. However, this does not rule out the possibility
of inaccuracy of the source data. Furthermore, no SBM-specific
treatment protocols existed, exemplified by the fact that the
Fig. 3. (A) Eight categories prior to merging. (B) Stratification model after merging. (C) Stratification model applied to Dutch Bone Metastasis Study
database.
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landmark study by Patchell et al.2 resulted in more surgical inter-
ventions being performed in the period after publication. How-
ever, as this study analyzes survival only and therapy for SBM is
not directly aimed at prolonging survival, it is unlikely that our
results are influenced by this change in therapeutic approach. It
is possible that the presence of brain metastases is underrepre-
sented in this study population because whole-brain scans were
not routinely performed, contrary to thoracic and abdominal
scans. As a result, most of the patients with brain metastases
had symptomatic lesions. It is unclear whether asymptomatic
brain metastases have the same predictive value in this specific
patient population. Lastly, treatment for SBM in our institution
only takes place in symptomatic patients, and only patients trea-
ted locally for their SBM bymeans of surgery or radiotherapy were
included. As a consequence, patients with symptomatic SBM that
received only supportive care no were not represented in this
study.
In contrast to the previous study by our group, which was
based on a prospective database with only radiotherapy patients,
patients with a cervical SBM were not excluded, nor were patients
with renal cell carcinoma, leading to better generalizability of the
data. Because the prospective DBMS database was closed after
an inclusion period of 2.5 years, median follow-up times were dis-
tinctly different. Survival times in category A are therefore limited.
Since the DBMS inclusion criteria were stricter and contained
more patients with a favorable clinical profile and fewer with an
unfavorable profile, median survival times were better than in the
current database. However, as a nearly identical C score shows,
the presented model is still capable of stratification based on
the identified risk factors.
As has been established in the literature, primary tumor type
(represented by clinical profile in this study) was shown to be the
factor of greatest influence on survival in patients with symptom-
atic SBM.21 This means that an accurate and up-to-date tumor
classification is essential for prognostication. The positive effect
of new treatments, such as anti-VEGF therapy, will mean that sur-
vival with symptomatic SBM may increase considerably for cer-
tain tumors in the near future.22 Also, it is unclear whether
there is a difference in survival for patients with SBM from differ-
ent subtypes of the same primary cancer, as is the case in breast
cancer with estrogen, progesterone, and HER2 interactions.23
These topics should be the subject of further SBM-specific studies.
A poor performance status nearly doubles the risk of death
in all 3 clinical profiles and is the second most important variable
to assess in patients with SBM. Even though the Karnofsky score is
a subjective score and is highly susceptible to changes in neuro-
logical functioning, it remains an effective tool to assess a
patient’s general condition quickly. The use of a performance-
related score as risk factor when estimating survival is also super-
ior when compared to age, as age only gives an indirect measure
of a patient’s functional status. Contrary to the Tokuhashi and Van
der Linden models, the KPS was divided into 2 categories instead
of 3 to facilitate clinical decision-making.
To the authors’ best knowledge, this is the first study to de-
scribe how the effect of visceral and brain metastases differs
per primary tumor category. Overall, there was no influence of
brain metastases, and the effect of visceral metastases was
only marginal. However, after stratification for the clinical profile,
a statistically significant effect on survival for visceral and brain
metastases was found in the favorable category only. The pres-
ence of brain or visceral metastases was not associated with sur-
vival of patients in both the moderate and unfavorable profiles,
obviating the need for additional radiologic examinations in
these groups when estimating survival. Most likely, this is due to
the fact that survival in these 2 categories is already very short
based on the primary tumor, and the effect of visceral or brain
metastases therefore becomes negligible.
Even though neurological status is one of the most important
factors to consider when deciding on treatment, the presence of
Table 6. Groups based on multivariate analysis
Clinical Profile KPS VM/BRM MOS (95% CI) n (%) Category
Favorable 100%–80% No 31.2 (25.2–37.3) 116 (12) A
Favorable 100%–80% Yes 14.0 (6.8–21.1) 42 (4) B
Favorable 70%–10% No 18.6 (16.0–21.1) 87 (9) B
Favorable 70%–10% Yes 4.8 (2.3–7.3) 52 (5) C
Moderate 100%–80% N/A 12.5 (6.5–18.5) 97 (10) B
Moderate 70%–10% N/A 4.8 (4.0–5.6) 190 (19) C
Unfavorable 100%–80% N/A 4.5 (3.1–5.8) 132 (13) C
Unfavorable 70%–10% N/A 1.6 (1.4–1.9) 278 (28) D
Abbreviations: CI, confidence interval; MOS, median overall survival; VM/BRM, visceral and/or brain metastases.
Table 7. Survival times by training and validation data sets
Category MOS (95% CI) n (%) HR 95% CI P value
Training data set
A 31.2 (25.2–37.3) 116 (12) – – ,.001
B 15.4 (11.9–18.2) 226 (23) 1.8 1.4–2.3 ,.001
C 4.8 (4.1–5.4) 374 (37) 4.4 3.5–5.6 ,.001
D 1.6 (1.4–1.9) 278 (28) 9.3 7.2–12.1 ,.001
Validation data set
A 16.3 (11.1–21.6) 64 (19) – – ,.001
B 12.8 (9.5–16.0) 111 (33) 1.5 1.0–2.2 .029
C 7.0 (5.1–9.0) 91 (27) 2.8 1.9–4.1 ,.001
D 3.6 (2.6–4.6) 73 (21) 6 3.9–9.2 ,.001
Abbreviations: CI, confidence interval; HR , hazard ratio; MOS, median
overall survival.
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neurological deficit at the start of treatment does not directly in-
fluence survival in any of the 3 clinical profiles described in this
study. Rades et al. have shown that the time of developing
motor deficits is the most important factor predicting improve-
ment of neurological functioning after treatment.24 Neurological
status should therefore be viewed as an indication for treatment
rather than a predictive factor when estimating survival. Especial-
ly in the case of sudden paraplegia due to spinal cord compres-
sion, swift and decisive treatment is far more important than
estimation of survival because the possible benefits of treatment
in terms of quality of life far outweigh the possible risks in terms of
a short remaining lifespan. When assessing neurological deficit in
patients with SBM, the Frankel classification might not be the
most suitable tool because it was originally designed for categor-
izing spinal cord injury only. Neurological symptoms caused by
nerve root compression or compression of the cauda equina are
not covered, necessitating the development of a SBM-specific
classification for describing neurological deficit.
Even though the number and location of SBM influence treat-
ment options such as possibilities of surgical fixation and range of
radiation fields, they did not show a significant effect on survival.
Sixty-nine percent of all patients studied had more than one con-
firmed spinal metastasis. It was also possible that a large propor-
tion of patients classified as having a solitary metastasis actually
had occult lesions.25 Lastly, the presence of extraspinal bone me-
tastases was not associated with survival.
New Model
A flowchart was created to guide the stratification of patients
with symptomatic SBM (Fig. 4). Based on a maximum of 3
easy-to-obtain variables, patients were classified into 1 of 4 cat-
egories (A–D), each with a distinctly different estimated survival
time. The effect of this approach is particularly striking in patients
with a favorable clinical profile: by assessing 2 variables, the me-
dian survival is split from 18.6 months (95% CI, 15.1–22.1
months) overall down to 4.8 months (95% CI, 2.3–7.3 months)
and up to 31.2 months (95% CI, 25.2–37.3 months) (Table 7).
Harrell’s C statistic was almost identical when the new model
was applied to an external database, indicating good reproduci-
bility of our results. The current values of 0.71 and 0.69 indicate a
good predictive value of the model and, with a more accurate
classification of primary cancers into 1 of the 3 clinical profiles,
the value of C should rise even further.
This large data collection provides a better understanding of
how risk factors interact when stratified for primary tumor. It is
shown that clinical profile and performance status have a strong
impact on survival in all patients with symptomatic SBM. The
presence of visceral and/or brain metastases is associated with
a shortened survival only in patients with an unfavorable clinical
profile.
The model presented in this study can be used as a simple
stratification tool for patients presenting with symptomatic
SBM. Also, it can be used in future studies to compare efficacy
of radiotherapy regimens and various types of surgical interven-
tion, as well as studies into the effects on quality of life of different
treatment modalities.
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